Clover Health Investments, Corp. CLOV R2K
Company Overview
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.
Why Investors Should Care
Revenue has grown at a 26.8% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.92B (+40.3% YoY); net profit $-85.55M.
- Trailing 12 Months Year-on-year growth — revenue +62.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 26.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 26.83% |
| 1 Year: | 62.00% |
Stock Price Performance
| 1 Year: | +56.00% |
| 6 Months: | +77.27% |
| 3 Months: | +129.41% |
| 1 Month: | -1.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 26.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CLOV Clover Health Investments, Corp. R2K | 4.68 | -36.00 | $2.02B | 0.00% | -25.75% | -16.86% | 26.83% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 165.50M | 172.08M | 169.07M | 200.32M | 412.47M | 427.16M | 874.38M | 846.70M | 856.82M | 321.99M | 320.14M | 306.03M | 346.92M | 356.26M | 330.99M | 462.33M | 477.62M | 496.65M | 749.19M |
| Gross Profit | - | - | - | - | - | -46.03M | -9.16M | 12.66M | -12.09M | 17.02M | 47.20M | 75.88M | 70.24M | 81.76M | 107.91M | 81.21M | - | - | - | - |
| Operating Income | -17.63K | -26.63M | 23.17M | -21.62M | -119.09M | -181.86M | -149.25M | -87.48M | -102.73M | -74.10M | -79.70M | -28.88M | -33.62M | -22.70M | 7.19M | -8.79M | -1.27M | -10.56M | -24.38M | 27.33M |
| Net Income | -17.63K | -28.16M | 5.40M | 12.76M | -48.42M | -317.61M | -34.53M | -75.49M | -104.36M | -75.49M | -72.61M | -28.81M | -41.47M | -19.17M | 7.41M | -9.15M | -1.27M | -10.58M | -24.38M | 27.33M |
| Diluted EPS | - | - | 0.01 | 0.02 | -0.13 | -0.78 | -0.08 | -0.16 | -0.22 | -0.16 | -0.15 | -0.06 | -0.09 | - | - | - | 0.00 | - | - | 0.05 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 462.27M | 672.89M | 1.47B | 1.10B | 1.26B | 1.37B | 1.92B |
| Gross Profit | - | - | -79.18M | 22.73M | 257.33M | - | - |
| Operating Income | -183.20M | -92.71M | -636.99M | -286.66M | -205.33M | -45.75M | -85.53M |
| Net Income | -363.74M | -136.39M | -587.76M | -339.57M | -213.36M | -43.01M | -85.55M |
| Diluted EPS | -4.14 | -1.54 | -1.42 | -0.71 | -0.44 | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Oct 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 100.35K | 267.25M | 950.80M | 808.62M | 570.67M | 580.74M | 541.01M |
| Total Equity | -502.57M | 0 | -17.63K | -617.10M | 535.41M | 347.74M | 286.39M | 341.14M | 308.70M |
| Cash & Equivalents | - | - | 0 | 92.35M | 299.97M | 103.79M | 122.86M | 194.54M | 78.30M |
| Long Term Debt | - | - | - | 106.41M | 19.94M | 0 | - | - | - |
| Total Liabilities | - | - | 117.98K | 432.70M | 410.76M | 451.73M | 284.28M | 239.60M | 232.31M |
| Current Liabilities | - | - | 117.98K | 164.23M | 371.90M | 431.51M | 261.12M | 213.52M | 208.82M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -159.88M | -118.50M | -282.33M | -203.93M | -144.66M | 34.84M | -66.93M |
| Investing Cash Flow | -181.91M | 137.40M | -435.45M | 95.13M | 140.01M | 565.00K | 4.08M |
| Financing Cash Flow | 333.98M | 5.84M | 925.39M | -4.96M | -5.07M | -17.36M | -53.38M |
| Capital Expenditure | -23.00K | -693.00K | -723.00K | -4.47M | -584.00K | -1.56M | -2.04M |
| Free Cash Flow | -159.90M | -119.19M | -283.05M | -208.39M | -145.25M | 33.29M | -68.98M |
| Share Buybacks | 0 | 0 | 147.00K | 0 | 0 | 1.77M | 18.30M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | -5.4% | 2.1% | 20.4% | - | - |
| Operating Margin % | -39.6% | -13.8% | -43.3% | -26.1% | -16.3% | -3.3% | -4.4% |
| Net Margin % | -78.7% | -20.3% | -39.9% | -31.0% | -16.9% | -3.1% | -4.4% |
| ROE % | 2,063,053.7% | 22.1% | -109.8% | -97.7% | -74.5% | -12.6% | -27.7% |
| ROCE % | 1,039,073.2% | -90.0% | -110.0% | -76.0% | -66.3% | -12.5% | -25.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.39% | 31.84M | $153.47M |
| 2 | Vanguard Capital Management LLC | 3.94% | 16.98M | $81.85M |
| 3 | Geode Capital Management, LLC | 2.33% | 10.06M | $48.47M |
| 4 | State Street Corporation | 2.22% | 9.56M | $46.08M |
| 5 | Charles Schwab Investment Management, Inc. | 1.23% | 5.30M | $25.55M |
| 6 | PNC Financial Services Group, Inc. | 0.87% | 3.76M | $18.14M |
| 7 | Vanguard Portfolio Management LLC | 0.86% | 3.70M | $17.82M |
| 8 | Dimensional Fund Advisors LP | 0.79% | 3.42M | $16.47M |
| 9 | Renaissance Technologies, LLC | 0.79% | 3.40M | $16.40M |
| 10 | Northern Trust Corporation | 0.77% | 3.31M | $15.94M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLOV
CLOV (Nasdaq: CLOV) plans Rule 144 sale of 60765 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNZUZ1SjhqRkVzTjllZTFyakRBTl9OSjM4T1dleDd5Nk1yanRVYkhGWlVLOUxlTExxMFQ0WmNSRWZwbklSRVd0eTlsd2EtYTNnT3BVcGZhazRqVURNdVF2MVEwTHFjWG5oT0RpNE5zelR6V0p6NmFNYW9LYmt1LWdJdklRQVp6bDVaTXhDR1…
Clover Health (CLOV): 3 Reasons We Love This Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxORnFrd3YzeFFCWjc3TmdiMUhGRWJ4WHZTN2c4ejRhY0VjOUVTMlF3MFRTWGN6dmphODZ4bG44TWh2TDRieGNlblU2RE1PSEhlSUg0MExIdmt2TzBfckw3ZU1HMmlDVFNzdXVIRVNlalVrRElWZldWSlZVd3N2TFJuMUQyV2VHRzZEYkhhMz…
CLOV (CLOV) plans sale of 23,463 Class A common shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQb1V1c0VDUkJ4cElDZkhoeEF0MTRxYnlNWWZIWUxMY3VuMHNwQUVWNG1jRkR5RGs4MUVCcDNrVlBicTh6NGREcDFDRDhxbHRSTWFWaHhDOGQtUVFVUEZud2NNOW0xeXRuSDh2a09CcVAyZk9aeS1QX01mdHVadl9pLVUyVjNVUkI5Y3VpQ0…
Clover Health CEO Andrew Toy sells $1.67 million in stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNWXpUR0NfWjU0bDR6RXBLYWNuc25lT3haa2N1alhyaGktNVlxV1JDT2g1X29TNGVkcmlNTWhCTFd2RnZMNlMzdXpDekRVYXNVdGhnRFRDd0JGMTVHb3VoNXR6WkFoejhTM0R5Q1NBc3F6OHRSVVRka3laTkNRWUxGSnFKTzhnLUZDZE9hVj…
UBS Nearly Doubles Its Price Target on Clover Health (CLOV) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPekhSeDBZU1dwaVJHZ3VzY193RVRVejROOWp5V3VSVXVJNU9iN0dNNTBaaTNoX0NyVFpIaHhNZ3RBRjhQclpKRjlydU5seVo2RmhOOEV6YzNUMEJRU1JsNnRJTUdxNS16S1VOZ1F3TjhCSkpmRHNoTUt5YlF1R05iRmRvUWlhN3c4WkR4a3…
AMC Stock Short Squeeze | Dogecoin | CLOV Stock | Blackberry Stock | UONE Stock Anna Pettinelli (r1AlbZQxBq) - Mshale
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9FTlhTRGNaQ1pRbGpzQzFIMV9TUC0yZi1YSWVYNzg5aXVlNzJMUVc1YU03Rk01Q2lWdHRYVExXZU5DaW5ONnlfcC1Ra3Njc043TmpPWXRmdzM3bms2NlhwMQ?oc=5" target="_blank">AMC Stock Short Squeeze | Dogecoin | …
CLOV — Frequently Asked Questions
What is the current share price of Clover Health Investments, Corp. (CLOV)?
As of 2026-07-15 16:51 PDT, Clover Health Investments, Corp. (CLOV) trades at $4.68 on NasdaqGS. Its 52-week range is $1.70 to $5.41.
What is the market capitalisation of CLOV?
Clover Health Investments, Corp. (CLOV) has a market capitalisation of $2.02B on NasdaqGS.
What is the P/E ratio of CLOV?
CLOV trades at a trailing price-to-earnings (P/E) ratio of -36.00. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 7.46.
What is the return on equity (ROE) of CLOV?
CLOV has a return on equity (ROE) of -16.86%. Its return on capital employed (ROCE) is -25.75%.
Is CLOV a good stock to buy?
This page provides a data-driven analysis of Clover Health Investments, Corp. (CLOV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.